1. Cell Cycle/DNA Damage Epigenetics
  2. PARP Epigenetic Reader Domain
  3. PCIP-1

PCIP-1 is a PARP2 inhibitor. PCIP-1 recruits BET proteins to PARP2 to inhibit DNA repair, acts via event-driven pharmacology, and does not inhibit PARP-catalyzed PARylation. PCIP-1 inhibits DNA repair, thereby inducing synthetic lethality in homologous recombination-deficient cancer cells and increasing the sensitivity of PARP1-knockout cells. PCIP-1 can be used in the research of homologous recombination-deficient cancers, T-cell acute lymphoblastic leukemia, and BRCA-mutant cancers.

For research use only. We do not sell to patients.

PCIP-1

PCIP-1 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PCIP-1 is a PARP2 inhibitor. PCIP-1 recruits BET proteins to PARP2 to inhibit DNA repair, acts via event-driven pharmacology, and does not inhibit PARP-catalyzed PARylation. PCIP-1 inhibits DNA repair, thereby inducing synthetic lethality in homologous recombination-deficient cancer cells and increasing the sensitivity of PARP1-knockout cells. PCIP-1 can be used in the research of homologous recombination-deficient cancers, T-cell acute lymphoblastic leukemia, and BRCA-mutant cancers[1].

IC50 & Target[1]

PARP2

 

BET

 

In Vitro

PCIP-1 induces formation of a ternary complex between BRD4 bromodomain 1 and PARP1 catalytic domain in vitro, as measured by HTRF signal[1].
PCIP-1 (Up to 50 µM; 2 h pre-incubation with PCIP-1, followed by 45 min incubation with dBET6) shows weak, non-saturating engagement of BRD4 in Jurkat-BRD4-HiBit cells, with an EC50 of 26 µM, and its anti-proliferative activity is not driven by occupancy-based BRD4 inhibition[1].
PCIP-1 (1 nM-100 μM; 72 h) potently inhibits Jurkat T-cell viability with an IC50 of 662 nM, and its activity is enhanced over 14-fold (IC50 = 45 nM) in the presence of the DNA-damaging agent MMS[1].
PCIP-1 (1 µM; 4 h) induces proximity between BET proteins (BRD4) and PARP1/2 in 22Rv1 cells, as shown by increased co-immunoprecipitation of these protein pairs[1].
PCIP-1 (100 nM-10 µM; 24 h) inhibits repair of MMS-induced DNA damage and induces apoptosis in Jurkat cells, without inhibiting global PARP-catalyzed PARylation[1].
PCIP-1 (100 nM-1 µM; 24 h) induces S-phase cell cycle arrest in Jurkat cells, consistent with inhibition of DNA damage repair[1].
PCIP-1 (1 µM; up to 14 days) reduces the competitive fitness of PARP2-proficient Jurkat-Cas9 cells, such that PARP2-deficient cells are selectively enriched, demonstrating PARP2 dependence of PCIP-1 activity[1].
PCIP-1 (0.1 nM-10 μM; 6 days) exhibits synthetic lethality with BRCA2 deficiency in DLD1 colon cancer cells, with BRCA2K/O cells showing over 100-fold greater sensitivity than parental cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Jurkat T-cell acute lymphoblastic leukemia (T-ALL) cells
Concentration: 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM
Incubation Time: 72 h
Result: Inhibited Jurkat cell viability with an IC50 of 662 nM.
Improved the IC50 to 45 nM in the presence of 25 µM methyl methanesulfonate (MMS).

Western Blot Analysis[1]

Cell Line: Jurkat T-cell acute lymphoblastic leukemia (T-ALL) cells
Concentration: 100 nM-10 µM (24 h incubation); 1 µM (time-course incubation)
Incubation Time: 24 h (dose-response); 12, 16, 24 h (time-course)
Result: Induced accumulation of the DNA damage marker γH2AX, especially with MMS.
Caused dose-responsive and time-dependent increases in cleaved PARP1/2 and cleaved Caspase 3.
Showed minimal effects on global PARylation levels.

Cell Cycle Analysis[1]

Cell Line: Jurkat T-cell acute lymphoblastic leukemia (T-ALL) cells
Concentration: 100 nM, 1 µM
Incubation Time: 24 h
Result: Induced a strong S-phase arrest.
Molecular Weight

833.41

Formula

C45H46ClFN8O3S

SMILES

O=C(NCC1)C2=CC(F)=CC3=C2C1=C(N3)C4=CC=C(NC(CCCCCCCCNC(C[C@@H]5N=C(C6=CC=C(Cl)C=C6)C(C(C)=C(C)S7)=C7N8C5=NN=C8C)=O)=O)C=C4

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PCIP-1
Cat. No.:
HY-185459
Quantity:
MCE Japan Authorized Agent: